PEG-Functionalized Mesoporous Nanoparticles for Controlled Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesoporous silica nanoparticles (MSNs) face challenges such as rapid clearance, burst drug release, and non-specific uptake in cancer therapy due to their size and dissolution mechanisms, leading to potential toxicity and limited clinical application.
Innovation Solution
Development of polyethylene glycol (PEG) functionalized mesoporous oxide nanoparticles with an average size of 15 nm or less, having a narrow size distribution and a portion of their surface functionalized with PEG groups, allowing for controlled drug delivery and imaging applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If mesoporous silica nanoparticles are used for drug delivery, then they can deliver multiple types of cargo into cells and tissues, but they require a fairly long time to dissolve under physiological conditions resulting in potential particle accumulation and long-term toxicity
Solution Approach 1:
The patent changes the particle size parameter from conventional larger sizes to ultra-small sizes (5-50 nm), which fundamentally alters the dissolution kinetics and enables rapid dissolution while maintaining cargo delivery capability. This parameter change resolves the contradiction by making the particles small enough to dissolve quickly before accumulating to toxic levels.
Solution Approach 2:
The patent segments the silica particle into ultra-small nanoscale units with controlled pore structures, increasing the surface area to volume ratio and enabling faster dissolution rates while preserving the mesoporous cargo-holding capability. The segmentation into smaller units allows both therapeutic function and safe elimination.
2Adaptability or versatility
If the size of MSNs is reduced to less than 10 nm to achieve additional therapeutic properties, then ultra-small silica nanoparticles can be developed, but the synthesis of fluorescent MSNs smaller than 10 nm with narrow particle size distributions remains a challenge
Solution Approach 1:
The patent uses surfactant templates as intermediary structures during synthesis to control and standardize particle formation. The surfactant micelles act as molds that guide silica deposition into uniform ultra-small particles with consistent sizes and narrow distributions, solving the manufacturing precision challenge.
Solution Approach 2:
The patent optimizes synthesis parameters including pH, temperature, and precursor ratios to control nucleation and growth rates, enabling precise control over particle size and distribution. By adjusting these parameters, the patent achieves narrow size distributions even at ultra-small dimensions below 10 nm.
3Stability of the object's composition
If conventional MSNs are used, then they have high-surface area and stability, but they exhibit rapid clearance and non-specific uptake
Solution Approach 1:
The patent changes the surface chemistry parameters by introducing PEGylation and other functional groups that modify protein corona formation and cellular recognition. This parameter change reduces non-specific uptake and clearance while preserving the structural stability and cargo delivery function of the mesoporous silica particles.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEG-functionalized nanoparticles achieve targeted drug delivery and imaging with improved stability and reduced toxicity, enhancing their potential for clinical applications by maintaining a narrow size distribution and controlled release of therapeutic agents.
Implementation Method 1
forming a reaction mixture in an aqueous solvent having a basic pH comprising: i) a surfactant, and ii.) an oxide precursor (e.g., a silica precursor such as TMOS)
Implementation Method 2
holding the reaction mixture at a temperature and for a time such that mesoporous oxide (e.g., silica) nanoparticles are formed
Implementation Method 3
adding a PEG-functionalized oxide (e.g., a PEG-functionalized silica) precursor, d) holding the reaction mixture at a temperature and for a time such that the PEG-functionalized mesoporous oxide (e.g., silica) nanoparticles are formed
Data Source
AI summary
Mesoporous oxide nanoparticles, compositions comprising such nanoparticle, and methods of making and using such nanoparticles. The nanoparticles (e.g., compositions comprising the nanoparticles) have an average size of less than 15 nm and a narrow size distribution. The nanoparticles can be used in imaging applications and delivery of molecular cargo (e.g., a drug) to an individual.